April SAS-B figures: pastilles hit nearly one-third of approvals by Adam Sheldon May 7, 2026May 7, 2026 Approvals through the Special Access Scheme fell below 20,000 in April, as pastilles continued to cement […]
Medicinal cannabis adverse event study provides useful early warnings, but with limitations by Dr Teresa Nicoletti and Geoff Bloom May 7, 2026May 7, 2026
‘Fitness, fresh air and forward thinking’: Cape to Cape for Cannabis delivers a new kind of industry event by Paul Mavor May 6, 2026June 8, 2026
Don’t get caught napping: here’s why you should enter the Cannabiz Awards 2026 by Martin Lane May 6, 2026June 8, 2026
Creditors progress Cannim recovery plan but doubts emerge over returns by Adam Sheldon May 6, 2026May 6, 2026
New platform connects clinicians with boutique Australian growers by Adam Sheldon May 5, 2026May 5, 2026
LGP reports full year revenue growth but domestic sales slide by Steve Jones April 30, 2026April 30, 2026
